In this study, by co-culturing tumor antigen-pulsed DCs with CIKs, we obtained the k-ras-DCCIKs, which have more prominent oncotherapy effect and more powerful tumor inhibition than CIKs and show a favourable application prospect. This evidence concerns the gene KRAS and neoplasm.